Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Core Viewpoint - Immuron Limited, an Australian biopharmaceutical company, is set to present at the Emerging Growth Conference on June 13, 2024, highlighting its innovative products and growth potential [1][4]. Company Overview - Immuron Limited (ASX: IMC; NASDAQ: IMRN) focuses on developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases [7]. - The company’s flagship product, Travelan®, is an orally administered passive immunotherapy that reduces the likelihood of travelers' diarrhea caused by pathogenic bacteria [8][9]. Conference Details - CEO Steven Lydeamore will present for 12 minutes at 2:00 PM US Eastern Standard Time and will address questions from attendees [2]. - The conference aims to connect public companies with individual and institutional investors, showcasing new products and major announcements [4][5]. Product Information - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies that binds to diarrhea-causing bacteria, preventing colonization [8]. - The product is registered in Australia and licensed in Canada, and it is sold as a dietary supplement in the U.S. for digestive tract protection [9]. Technology Platform - Immuron's proprietary technology utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, allowing for the development of medicines targeting various infectious diseases [11]. - The platform can produce specific immunoglobulins that remain active in the gastrointestinal tract, effectively neutralizing pathogens [11].